



Nordic Alzheimer Disease Symposium
Friday 5th September 2025
Time | Content | Speaker |
---|---|---|
12.00-13.00 | Lunch | |
13.00-13.10 | Welcome | BioArctic, Eisai and the Steering Committee |
13.10 -13.15 | Chapter 1 ABC of AD – where are we now? | Chair: Dag Årsland (NO) Co-chair: Silke Kern (SE) |
13.15-13.35 | Current understanding of the AD pathology | Heikki Tanila (FI) |
13.35- 13.55 | Diagnostic procedures and criteria for AD | Niklas Mattsson-Carlgren (SE) |
13.55-14.15 | Epidemiology of AD | Ingmar Skoog (SE) |
14.15-14.35 | Leg stretch. Coffee and refreshments. | |
14.35-14.40 | Chapter 2 Early diagnosis and biomarkers in AD | Chair: Silke Kern (SE) Co-chair: Tormod Fladby (NO) |
14.40-15.00 | Fluid biomarkers | Henrik Zetterberg (SE) |
15.00 -15.20 | Imaging in AD | Tobias Granberg (SE) |
15.20-15.40 | Panel discussions Chapter 2 – Nordic country perspectives | Johanna Krüger & Eino Solje (FI), Kristian Steen Frederiksen (DK), Henrik Zetterberg (SE), Tormod Fladby (NO) |
15.40-16.00 | Leg stretch. Coffee and refreshments | |
16.00-16.05 | Chapter 3 Treatment of Alzheimer disease | Chair Anne Koivisto, Co-chair: Miia Kivipelto |
16.05-16.25 | Alzheimer’s disease – non-pharmacological interventions | Miia Kivipelto (SE/FI) |
16.25-16.45 | Anti-amyloid antibodies – clinical efficacy and safety data overview | Eino Solje (FI) |
16.45-17.05 | Future drug candidates for AD therapy | Kristian Steen Frederiksen (DK) |
17.05-17.25 | Conceptualizing future AD treatment? – Q&A (interactive Chapter) | Anne Koivisto (FI), |
17.25-17.30 | Technical break | |
17.30-18.20 | Clinical experience with anti-amyloid treatments in the US | Marwan Noel Sabbagh (US), Barrow Neurological Institute |
18.20-18.40 | Open Q&A session | |
18.40-18.45 | Wrap up day 1 | Chairs: Silke Kern (SE), Kristian Steen Frederiksen (DK), Anne Koivisto (FI), Dag Årsland (NO) |
19.30 | Dinner |
Saturday 6th September 2025
Time | Content | Speaker |
---|---|---|
07.00-08.30 | Breakfast | |
08.30-08.35 | Opening of day 2 | BioArctic, Eisai and the Steering Committee |
08.35-08.40 | Chapter 4 Management in Alzheimers disease | Chair: Kristian Steen Frederiksen (DK) Co-chair: Riitta Parkkola (FI) |
08.40-09.00 | Cognitive and functional assessments and digital opportunities | Hanneke Rhodius-Meester (NO/NL) |
09.00-09.20 | Understanding ARIA | Tiago Gil Oliveira (PT), School of Medicine, University of Minho |
09.20-09.40 | Q&A | |
09.40-10.00 | Leg stretch. Coffee and refreshments. | |
10.00-10.05 | Chapter 5 Societal and ethical perspectives of Alzheimers disease | Chair: Anne Koivisto (FI) Co-chair: Ingmar Skoog (SE) |
10.05-10.25 | Ethical aspects of early diagnosis and treatment | Bjørn Hofmann (NO) |
10.25-10.45 | Efficacy & safety communication vs patient expectations | Anne-Rita Øksengård (NO) |
10.45-11.05 | Alzheimer costs and impact of DMTs* for the society? | Linus Jönsson (SE) |
11.05-11.25 | AD DMT* registries in Nordic – future needs? + Discussion | Maria Eriksdotter (SE) Jaakko Hotta (FI), Anne Koivisto (FI) |
11.25-11.45 | Open Q&A session | |
11.45- 12.00 | Wrap up and closing of symposium | BioArctic, Eisai and the Steering Committee |
12.00- | Lunch Grab & Go |
* Disease Modifying Therapies

